What question did this study set out to answer?

Evaluate the real-world effectiveness of l-glutamine in Texas Medicaid enrollees with sickle cell disease.

December 8, 2025Blood

Real-world effectiveness of l-glutamine in Texas Medicaid patients with sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort study shows l-glutamine's limited impact on acute complications in sickle cell disease patients.

Evaluate the real-world effectiveness of l-glutamine in Texas Medicaid enrollees with sickle cell disease.
Retrospective cohort study using Texas Medicaid claims data from July 2017 to August 2023.
Identified patients with sickle cell disease using ICD-10-CM diagnosis code and analyzed those with l-glutamine prescriptions.
Propensity score matching was used to balance baseline characteristics of users and non-users.
Outcomes included VOC events, emergency department visits, inpatient stays, and acute chest syndrome during a 1-year follow-up.
113 patients in the l-glutamine user group had no significant changes in VOC events or emergency department visits post-treatment.
Users experienced more VOC episodes and earlier onset of first and second VOC events compared to non-users.
In subgroup analysis, l-glutamine users for 6 months had higher incidence of VOCs and odds of ACS events.

Kang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark